Summary.-Female C3H/HeJ mice bearing intramuscularly transplanted KHT sarcomas were treated with a single dose of 1,3-bis (2-chloroethyl)-l-nitrosourea (BCNU, 30 mg/kg, i.p.) alone or in combination with a single dose of misonidazole (MISO, 1-0 mg/g, i.p.) or its desmethylated metabolite Ro-05-9963 (2.0 mg/g, i.p.).
ventional therapeutic agents, in this particular case a nitrosourea, to produce an enhanced tumour response. The production of such a response appears to be nitroimidazole as well as schedule dependent. THE radioprotective effect of hypoxia has been well established and the presence of oxygen-deficient cells has been shown to limit tumour control by single and fractionated doses of radiation in many animal tumour models. More recently, hypoxic cells in EMT-6 spheroids (Sutherland et al., 1978 hypoxic, exponentialphase cells in monolayer culture (RoizinTowle & Hall, 1978; Smith et al., 1979; Sutherland et al., 1978 Sutherland et al., , 1979 as well as hypoxic tumour cells in vivo (Hill & Stanley, 1975; Hill & Bush, 1977) have been shown to be refractory to treatment with several conventional cancer chemotherapeutic agents. Realization of the potential significance of hypoxic cells in limiting the effectiveness of conventional chemotherapy has led to the design and evaluation of experimental protocols combining commonly used anti-tumour drugs with nitroimidazoles, which, in addition to sensitizing hypoxic cells to radiation, have been shown to be preferentially cytotoxic to hypoxic tumour cells Brown, 1977; Conroy et al., 1980; Mohindra & Rauth, 1976; Moore et al., 1976; Olive & Durand, 1978; Stratford & Adams, 1977; Sutherland, 1974; Sutherland et al., 1980) . For example, Sutherland et al. (1979) have reported that pretreatment with misonidazole (MISO) before Adriamycin significantly reduced the Adriamycin-resistant population in EMT-6 spheroids. Iso-effect analysis of these data suggested that the combination of Adriamycin and MISO resulted in apparent supra-additive cytotoxicity . Likewise, Rose et al. (1980) have demonstrated enhanced cytotoxicity in Lewis lung tumours treated in vivo with combinations of MISO and various alkylating agents. We therefore designed experiments to evaluate the relative effectiveness of several drug administration schedules combining MISO, or its desmethylated metabolite with the clinically useful alkylating agent 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in the treatment of KHT tumours in vivo.
MATERIALS AND METHODS
For these experiments 2 x 105 KHT (Kallman et al., 1967) tumour cells were injected i.m. into the right calf of 8-12-week-old female C3H/HeJ mice. Animals were sorted and randomized into the appropriate control and experimental groups when the tumours had grown to 0-2 g. BCNU (30 mg/kg) and MISO (1.0 mg/g) or 9963 (2-0 mg/kg) were injected i.p. according to the administration schedules outlined in Tables I and II. BCNU was initially dissolved in 100% ethanol at a concentration of 30 mg/ml, and then diluted to a final concentration of 1-5 mg/ml with physiological saline immediately before injection. MISO and 9963 were dissolved in PBS at concentrations of 20 and 40 mg/ml respectively.
The relative effectiveness of the various drug-treatment combinations was evaluated in a tumour growth-delay assay. Tumour size was measured daily by passing the tumourbearing leg through a series of increasing diameter holes in a Plexiglass rod. This measurement was then converted to a tumour weight by using a calibration curve obtained by excising and weighing tumours of measured diameters from the legs of untreated animals (Siemann et at., 1977) . Growth delay was then determined by measuring the difference in time required for treated tumours to grow to 4 x the initial treatment size (weight) relative to that required for untreated tumours.
Five to 7 animals were routinely included in the control and treatment groups for each experiment. Groups listed in Tables I and II as having n > 7 represent the pooled data from 2-4 replicate experiments. Drug-related toxic deaths refer to the number of animals which died during the tumour-measurement period without metastatic tumour involvement of the lungs.
The time required for individual tumours to grow to a size 4 x the treatment size was not normally distributed within some of the treatment groups; thus, the results are reported and compared using median growthdelay values. The non-parametric Wilcoxon rank-sum test was used for statistical analysis. . Table I and Fig. 1 . A median tumour growth delay of 9 days was produced when animals were treated with 9963 3 h after BCNU. This response was significantly greater than that after BCNU alone (P < 0 01). However, tumour growth delay following all other combinations of 9963 and BCNU was not significantly different from growth delay produced by BCNU alone.
The results of the combination MISO-BCNU experiments are summarized in Table II (Sutherland, 1974; Sutherland et al., 1976) as a means of overcoming the recently demonstrated chemoresistance of hypoxic mammalian cells. MISO, an electronaffinic nitroimidazole currently being clinically evaluated as a radiation sensitizer, is preferentially cytotoxic to hypoxic cells Brown, 1977; Conroy et al., 1979; Stratford & Adams, 1977; Sutherland et al., 1980) and is capable of enhancing the cytotoxicity of certain anti-tumour agents to cells in EMT-6 spheroids and Lewis lung tumours in vivo (Rose et al., 1980) . In order to exploit this type of enhanced cytotoxicity therapeutically most efficiently, it is essential to evaluate various drug administration schedules. In addition, it is conceivable that potentially less toxic nitroimidazoles, such as 9963, may also be advantageously administered in conjunction with conventional chemotherapeutic drugs. Therefore, we designed experiments to investigate the response of KHT tumours in vivo to a series of treatment combinations of MISO, or its desmethylated metabolite Ro-05-9963, with BCNU, which has been shown to be relatively ineffective against the hypoxic cells of B16 melanomas (Hill & Stanley, 1975) .
Although neither MISO nor 9963 delayed the growth of KHT tumours when administered alone, both were capable of enhancing tumour response to BCNU treatment, provided they were injected at appropriate times relative to BCNU administration. MISO significantly improved tumour response in more of the combinations evaluated (4/9) than did 9963 (1/9). Interestingly, however, MISO reduced BCNU effectiveness when given 3 h before BCNU, whereas a similar combination of 9963 produced a slight, though not significant, increase in growth delay. These results emphasize the importance of considering the drug injection schedule when evaluating combination chemotherapy with nitroimidazoles. They further demonstrate that an effective combination for one nitroimidazole is not necessarily predictive of similar effectiveness when the combination includes a different nitroimidazole. The effectiveness of combined nitroimidazole-BCNU chemotherapy treatment of KHT tumours in vivo is, therefore, both nitroimidazole and schedule dependent.
The enhancement of tumour growth delay was similar for all effective drug combinations. The additional growth delay of 2 days is equivalent to about one doubling time for KHT tumours over the size range used in these studies. Although killing of hypoxic cells by the nitroimidazoles is probably partially responsible for the observed enhancement, it seems likely that other factors may be involved, particularly since positive interactions were only produced in response to simultaneous BCNU-MISO administration or to addition of nitroimidazoles more than one hour after BCNU. Other possible contributory factors might include: altered pharmacokinetics and bioavailability of BCNU or the sensitizers, nitroimidazole-induced inhibition of the repair of sub-lethal or potentially lethal BCNU damage, BCNU-induced sensitization to the cytotoxic action of the nitroimidazoles, or conversely, nitroimidazoleinduced sensitization to BCNU. In preliminary clonogenic assays we have seen no evidence for repair of sublethal or potentially lethal damage in KHT tumours after BCNU treatment. Therefore, repair inhibition by the nitroimidazoles does not seem to be a plausible explanation for our results. Considering the short plasma halflife (Oliverio, 1973) of the parental BCNU compound, it seems improbable that addition of sensitizer several hours after BCNU could substantially alter its bioavailability. However, it is conceivable that such combinations could profoundly influence the metabolic detoxification of reactive daughter products. Prolonged exposure to cytotoxic, nitrosourea-related degradation products or alternatively, a mechanism involving direct or indirect BCNU-induced sensitization to nitroimidazole cytotoxicity, would at the present seem most consistent with our observations. Experiments designed to further evaluate these various possibilities are in progress.
In spite of encouraging tumour results, combination chemotherapy with nitroimidazoles will prove to be of therapeutic benefit only if the magnitude of the enhanced tumour response exceeds the enhancement of any normal tissue toxicity due to such combinations.
Although the numbers of animals observed were small, in terms of animal deaths, some of the combinations studied appeared to be more toxic than might be expected from a consideration of the single-agent toxicities. However, in 3 replicate experiments two of the more effective combinations (MISO given at the same time as or 3 h after BCNU) resulted in little or no drug-related lethality.
We have performed preliminary experiments to further evaluate the normal tissue toxicity resulting from simultaneous treatment with MISO and BCNU. Depression of the peripheral white-cell count, a major toxicity associated with BCNU treatment (Katz & Glick, 1979) was not significantly different between groups of animals treated with BCNU alone or in combination with MISO. Likewise, rotorod performance, a measure of peripheral neuropathy (Conroy et al., 1979) one of the major dose-limiting toxicities experienced in clinical trials with MISO (Dische et al., 1978) was not significantly different between groups of animals which received MISO alone or in conjunction with BCNU. Experiments designed to quantitate and compare tumour and normal tissue enhancement ratios are in progress. However, our current results are consistent with those of Rose et al. (1980) suggesting that combination chemotherapy including nitroimidazoles may enhance tumour response without equally enhancing normal tissue toxicity.
In conclusion, we have demonstrated that combining BCNU with the radiation sensitizers misonidazole and Ro-05-9963 can enhance KHT tumour response as determined with a growth-delay assay. The production of such a response is nitroimidazole and schedule dependent. Some of the combinations which were effective in enhancing tumour response did not increase drug-related deaths, thus suggesting a potential therapeutic advantage. This therapeutic approach may be particularly advantageous in the treatment of widespread metastatic disease, where localized radiation therapy is impractical and the success of conventional chemotherapy is limited by the presence of chemoresistant hypoxic tumour cells and overlapping normal tissue toxicities.
